Exagen Inc. Share Price & Technical Analysis
XGN · $4.26 (-0.23%)
Healthcare / Diagnostics & Research
$4.26
-0.23%
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testi…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
48% return in May, 28% avg return in past 3 year May month.
-11% return in 2026, 67% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -39% | 0% | -17% | -3% | 48% | – | – | – | – | – | – | – | -11% |
| 25 | -2% | -8% | 9% | 77% | 10% | 1% | 22% | 21% | 13% | 6% | -33% | -22% | 94% |
| 24 | 16% | 5% | -27% | -12% | 54% | -5% | 11% | 50% | 7% | -20% | 67% | -9% | 135% |
| 23 | 12% | -14% | -4% | 9% | 20% | -6% | -17% | 4% | -8% | -29% | 6% | 0% | -27% |
| 22 | -16% | -23% | 5% | -25% | -18% | 14% | 28% | -40% | -36% | -11% | 4% | -11% | -129% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$86.19M
P/E ratio
—
52W high
$12.23
52W low
$2.59
Volume
3,87,221
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Exagen Inc. share price today?
- Exagen Inc. (XGN) last traded around $4.26 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does XGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for XGN. Download the app for real-time alerts.
- How can I analyze Exagen Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.